New Treatment Options for DLBCL: Impact on Sequencing Therapeutic Choices - Episode 12

R/R DLBCL: Safety Considerations for Bispecific Antibodies

, , , , ,

A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma
    EP. 2: Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL
    EP. 3: Treatment Selection in Second Line R/R DLBCL
    EP. 4: Tafasitamab and Lenalidomide for R/R DLBCL
    EP. 5: Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL
    EP. 6: The Role of CAR T-Cell Therapy in R/R DLBCL
    EP. 7: Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL
    EP. 8: Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma
    EP. 9: Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL
    EP. 10: Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting
    EP. 11: Bispecifics for Third Line Therapy of R/R DLBCL
    Now Viewing
    EP. 12: R/R DLBCL: Safety Considerations for Bispecific Antibodies
    EP. 13: Treatment Sequencing of Later Line Therapies in R/R DLBCL
    EP. 14: Additional Data Updates from ASH 2023
    EP. 15: Future Outlooks in the Treatment of R/R DLBCL
    x